Belatacept

From WikiProjectMed
Jump to navigation Jump to search
Belatacept
Names
Trade namesNulojix
Clinical data
Drug classT cell activation inhibitor[1]
Main usesKidney transplant[2]
Side effectsLow red blood cells, diarrhea, urinary tract infection, swelling, constipation, fever, cough, nausea, low or high potassium[2]
Pregnancy
category
  • AU: C
  • US: N (Not classified yet)
Routes of
use		Intravenous
Typical dose5 to 10 mg/kg[3]
External links
AHFS/Drugs.comMonograph
MedlinePlusa606016
Legal
License data
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only

Belatacept, sold under the brand name Nulojix, is a medication used to prevent rejection following a kidney transplant.[2] It is used with corticosteroids and mycophenolic acid.[3] Use in the United Kingdom is not generally recommended.[1] It is given by injection into a vein.[3]

Common side effects include low red blood cells, diarrhea, urinary tract infection, swelling, constipation, fever, cough, nausea, and low or high potassium.[2] Other side effects may include infections, cancer, and posttransplant lymphoproliferative disorder.[4] It is a recombinant fusion protein which acts as a T cell activation inhibitor.[1][4]

Belatacept was approved for medical use in the United States and Europe in 2011.[2][3] In the United Kingdom 250 mg costs the NHS about £355 as of 2021.[1] This amount in the United States is about 930 USD.[5]

Medical uses

Dosage

It is initially given at a dose of 10 mg/kg at the time of surgery.[3] Further doses are than given at days 5, 14, and 28 and at 8 and 12 weeks.[3] Further doses of 5 mg/kg are than given every 4 weeks.[3]

Chemistry

It is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4, which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. It differs from abatacept (Orencia) by only two amino acids.

References

  1. ↑ 1.0 1.1 1.2 1.3 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 893. ISBN 978-0857114105.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 "DailyMed - NULOJIX- belatacept injection, powder, lyophilized, for solution". dailymed.nlm.nih.gov. Archived from the original on 25 March 2021. Retrieved 8 January 2022.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 "Nulojix". Archived from the original on 22 June 2021. Retrieved 8 January 2022.
  4. ↑ 4.0 4.1 "Belatacept Monograph for Professionals". Drugs.com. Archived from the original on 24 November 2020. Retrieved 8 January 2022.
  5. ↑ "Belatacept Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 8 January 2022.

External links

External sites:
Identifiers:
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help MDWiki by expanding it.

Retrieved from "https://mdwiki.org/w/index.php?title=Belatacept&oldid=1375956"